Business Description
Modalis Therapeutics Corp
ISIN : JP3922600006
Share Class Description:
TSE:4883: Ordinary SharesDescription
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.87 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.15 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -74.5 | |||||
| 3-Year EPS without NRI Growth Rate | -64.9 | |||||
| 3-Year FCF Growth Rate | -17.4 | |||||
| 3-Year Book Growth Rate | -42.5 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.82 | |||||
| 9-Day RSI | 35.69 | |||||
| 14-Day RSI | 39.6 | |||||
| 6-1 Month Momentum % | 104.29 | |||||
| 12-1 Month Momentum % | 43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.91 | |||||
| Quick Ratio | 12.87 | |||||
| Cash Ratio | 12.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -133.46 | |||||
| ROA % | -106.66 | |||||
| ROIC % | -921.5 | |||||
| ROC (Joel Greenblatt) % | -4509.58 | |||||
| ROCE % | -116.77 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.61 | |||||
| Price-to-Tangible-Book | 3.62 | |||||
| EV-to-EBIT | -2.18 | |||||
| EV-to-EBITDA | -2.18 | |||||
| EV-to-FCF | -1.98 | |||||
| Price-to-Net-Current-Asset-Value | 3.88 | |||||
| Price-to-Net-Cash | 4.1 | |||||
| Earnings Yield (Greenblatt) % | -45.81 | |||||
| FCF Yield % | -39.7 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Modalis Therapeutics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | |||
| EPS (TTM) (円) | -64.98 | ||
| Beta | 0.71 | ||
| Volatility % | 158.86 | ||
| 14-Day RSI | 39.6 | ||
| 14-Day ATR (円) | 8.309571 | ||
| 20-Day SMA (円) | 114.45 | ||
| 12-1 Month Momentum % | 43 | ||
| 52-Week Range (円) | 62 - 203 | ||
| Shares Outstanding (Mil) | 56.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Modalis Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Modalis Therapeutics Corp Stock Events
| Event | Date | Price(円) | ||
|---|---|---|---|---|
| No Event Data | ||||
Modalis Therapeutics Corp Frequently Asked Questions
What is Modalis Therapeutics Corp(TSE:4883)'s stock price today?
The current price of TSE:4883 is 円102.00. The 52 week high of TSE:4883 is 円203.00 and 52 week low is 円62.00.
When is next earnings date of Modalis Therapeutics Corp(TSE:4883)?
The next earnings date of Modalis Therapeutics Corp(TSE:4883) is .
Does Modalis Therapeutics Corp(TSE:4883) pay dividends? If so, how much?
Modalis Therapeutics Corp(TSE:4883) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers